Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations

28 september 2026 uppdaterad av: Xentria, Inc.

Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

32

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Aalborg, Danmark, 9000
        • Xentria Investigative Site
      • Aarhus, Danmark, 8200
        • Xentria Investigative Site
      • Odense, Danmark, 5000
        • Xentria Investigative Site
      • Roskilde, Danmark, 4000
        • Xentria Investigative Site
      • Vejle, Danmark, 7100
        • Xentria Investigative Site
    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35233
        • Xentria Investigative Site
    • Colorado
      • Denver, Colorado, Förenta staterna, 80206
        • Xentria Investigative Site
    • Florida
      • Jacksonville, Florida, Förenta staterna, 32209
        • Xentria Investigative Site
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60611
        • Xentria Investigative Site
      • Chicago, Illinois, Förenta staterna, 60612
        • Xentria Investigative Site
    • Iowa
      • Iowa City, Iowa, Förenta staterna, 52242
        • Xentria Investigative Site
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Xentria Investigative Site
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48202
        • Xentria Investigative Site
    • Minnesota
      • Minneapolis, Minnesota, Förenta staterna, 55455
        • Xentria Investigative Site
    • New York
      • Albany, New York, Förenta staterna, 12208
        • Xentria Investigative Site
      • New York, New York, Förenta staterna, 10029
        • Xentria Investigative Site
    • North Carolina
      • Greenville, North Carolina, Förenta staterna, 27858
        • Xentria Investigative Site
    • Ohio
      • Cincinnati, Ohio, Förenta staterna, 45267
        • Xentria Investigative Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19140
        • Xentria Investigative Site
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Xentria Investigative Site
    • Virginia
      • Charlottesville, Virginia, Förenta staterna, 22903
        • Xentria Investigative Site
      • Bielsk Podlaski, Polen, 15-044
        • Xentria Investigative Site
      • Lodz, Polen, 90-153
        • Xentria Investigative Site
      • Barcelona, Spanien, 08035
        • Xentria Investigative Site
      • Barcelona, Spanien, 08036
        • Xentria Investigative Site
      • Seville, Spanien, 41013
        • Xentria Investigative Site
    • England
      • Coventry, England, Storbritannien, CV22DX
        • University Hospitals Coventry and Warwickshire NHS Trust
      • London, England, Storbritannien, SE59RS
        • King's College Hospital NHS Foundation Trust
      • London, England, Storbritannien, NW12PG
        • University College London Hospitals NHS Foundation Trust
      • Norwich, England, Storbritannien, NR47UY
        • Norfolk and Norwich University Hospitals NHS Foundation Trust
      • Oxford, England, Storbritannien, OX37LE
        • Oxford University Hospitals NHS Foundation Trust
    • Scotland
      • Perth, Scotland, Storbritannien, PH11NX
        • NHS Tayside
      • Prague, Tjeckien, 140 59
        • Xentria Investigative Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 80 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Participant between 18 to 80 years (inclusive) of age.
  2. Weighs between 45 kg and 160 kg (99 to 353 lbs) at Screening.
  3. Diagnosis of pulmonary sarcoidosis (at least 6 months before Screening) using the 2020 American Thoracic Society (ATS) Clinical Practice Guideline (Crouser et al, 2020), the European Respiratory Society (ERS) or the WASOG criteria including a compatible clinical and radiologic presentation with other causes of granulomatous disease ruled out (cutaneous and ocular involvement permitted).
  4. Modified Medical Research Conference (mMRC) Dyspnea Scale of ≥ 1.
  5. Receiving treatment of 7.5 to 25 mg/day of oral prednisone, or equivalent, during the screening period and, at the determination of the investigator, is capable of undergoing the protocol specific corticosteroid taper regimen.
  6. Receiving treatment with methotrexate, azathioprine, mycophenolate, leflunomide, chloroquine, or hydroxychloroquine for at least 3 months before Screening that has been at a stable dose for 4 weeks before Screening. All efforts should be made to maintain stable background therapy at the Screening dose through the intervention period at the Investigator's discretion.
  7. Willing to refrain from consumption of grapefruit or grapefruit juice [pomelos, exotic citrus fruits, or grapefruit hybrids] from screening visit until after the final dose.
  8. Polymerase chain reaction (PCR) test or rapid antigen test negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening.
  9. Able to provide written informed consent.
  10. In the opinion of the Investigator, the participant is capable of understanding and complying with protocol requirements

Exclusion Criteria:

  1. Pregnant or breastfeeding women or women who are planning to become pregnant during the study.

  2. Participants > 65 years of age. (This exclusion criterion is only applicable for EU).

  3. Known potentially significant fibrotic disease and/or active inflammation contained solely in the hilar region as shown by high-resolution computed tomography (HRCT), confirmed by a central reader. Participants with current active inflammation in the hilar region with concurrent inflammation outside the hilar region may be included.

    A historical HRCT performed within 6 months of screening may be submitted for diagnostic confirmation by central review. If a subject's last HRCT was from > 6 months of screening, an HRCT should be performed during screening for diagnostic confirmation by central review.

  4. Any prior TNFα inhibitor therapy.

  5. Clinically significant extra-pulmonary sarcoidosis requiring systemic therapy as determined by the investigator.

  6. Baseline percent predicted forced vital capacity (FVC) of < 50%.

  7. Prior treatment with rituximab or repository corticotropin injection within the previous 12 months.

  8. Clinically significant Central Nervous System (CNS) sarcoidosis requiring therapy, except history of isolated seventh cranial nerve palsy or evidence of demyelinating neurologic disease.

  9. Advanced congestive heart failure (New York Heart Association [NYHA] 3 or 4).

  10. Current disease presentation consistent with Lofgren's syndrome (i.e., presence of the triad of erythema nodosum, bilateral hilar lymphadenopathy on chest X-ray, and joint pain).

  11. Clinically significant pulmonary hypertension requiring treatment. Note: Clinically significant pulmonary hypertension requiring treatment would be defined as treatment with, i.e., prostacyclins, phosphodiesterase 5 inhibitors, and endothelin receptor antagonists.

  12. Known hypersensitivity to any component of the formulation of XTMAB-16.

  13. Live or messenger ribonucleic acid (mRNA) vaccination within 2 weeks before Day 1 or inoculation with a live or mRNA vaccine is planned during study participation.

  14. Evidence of active or latent TB by interferon-gamma release assay (IGRA) or invasive fungal infections at Screening.

  15. Known positive history of malignancy other than non-melanomatous skin cancer in the last 2 years, including in-situ carcinoma of the uterine cervix completely cured by radical surgery.

  16. Positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, coronavirus disease (COVID-19), TB, or a known history of human immunodeficiency virus (HIV) infection at Screening.

  17. Women of childbearing potential who are sexually active with a non-sterilized male partner and are not willing to adhere to highly effective birth control measures from the time of signing the informed consent, throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since the last dose of study drug.

  18. Male participants who are non-sterilized and sexually active with a female partner of childbearing potential and are not willing to use highly effective contraception from the time of signing the informed consent throughout the duration of the study, and for 90 days after 5 half-lives have elapsed since last dose of study drug.

  19. Clinically significant hepatic or renal disease, including uncontrolled diabetes at the discretion of the investigator.

  20. Any severe prior reaction to any type of biologics or human blood product such as albumin, IgG, etc.

  21. Concurrent emphysema.

  22. Known hypercalcemia due to non-sarcoidosis conditions such as untreated hyperparathyroidism, at the discretion of the investigator.

  23. Abnormal ECG: ventricular arrhythmias (non-sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions, bundle branch block, axis deviation, or abnormal Q waves). In the case of a QTcF (corrected QT interval by Fredericia) interval > 450 ms (men) or > 480 ms (women; participants with bundle branch block) or PR interval outside the range of 120 to 220 ms, the assessment may be repeated once for eligibility determination at Screening or Baseline.

  24. Donation or loss of 450 mL or more of his or her blood volume (including plasmapheresis) or transfusion of any blood product within 90 days prior to dosing.

  25. Known uncontrolled hypertension. Note: Uncontrolled hypertension is noted as blood pressure ≥ 160/100 mmHg despite antihypertensive therapy within 3 months of randomization.

  26. Clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue, new smell or taste disorder or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening.

  27. In the opinion of the investigator, inability to tolerate corticosteroid taper.

  28. Concurrent systemic steroid use for non-sarcoidosis conditions.

  29. Concurrent known auto-immune disease requiring treatment.

  30. Participation in another clinical trial of an investigational agent within 3 months (small molecule) / 6 months (biologics) or 5 half-lives (if known) of the agent, whichever is longer.

  31. Any condition that required hospitalization within the 3 months prior to Day 1 or is likely to require so during the study.

  32. Clinically significant abnormalities in the Screening physical exam, medical history, vital signs, ECG, or clinical laboratory tests that are not known to be due to concurrent sarcoidosis, and in the opinion of the Investigator and Medical Monitor should preclude the participant's participation in the clinical study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Del A - XTMAB-16: 2 mg/kg var 4:e vecka (Q4W) i 12 veckor eller placebo

Infusion

Experimentell: Del A - XTMAB-16: 4 mg/kg var 4:e vecka (Q4W) i 12 veckor eller placebo

Infusion

Experimentell: Del A - XTMAB-16: 2 mg/kg varannan vecka (Q2W) i 12 veckor eller placebo

Infusion

Experimentell: Del A - XTMAB-16: 4 mg/kg varannan vecka (Q2W) i 12 veckor eller placebo

Infusion

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Rate of Adverse Events (AEs), including Serious Adverse Events (SAEs), Dose Limiting Toxicities (DLTs), and Adverse Events of Special Interests (AESIs) throughout the study duration
Tidsram: Throughout Study Duration, 20 weeks

To evaluate the safety and tolerability of multiple ascending doses of XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Throughout Study Duration, 20 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacokinetic (PK) profile including trough concentration (Ctrough)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including maximum concentration (Cmax)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including average concentration (Caverage)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacokinetic (PK) profile including area under the curve (AUC)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized maximum serum concentration (Cmax/D)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve over the dosing interval (AUCtau/D)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve from time 0 to the time of the last quantifiable concentration observed (AUClast/D)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Dose normalized area under the concentration time curve from time 0 extrapolated to infinity (AUCinf/D)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Pharmacodynamics (PD) markers, including: Angiotensin converting enzyme (ACE), Soluble IL-2 receptor (sIL 2R), C-reactive protein (CRP), Interleukin-1b (IL-1b) and Calcitriol (vitamin D 1, 25)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Occurrence and persistence of anti-drug antibodies (ADA)
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Mean percent change in forced vital capacity (FVC)%
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Change in King's Sarcoidosis Questionnaire (KSQ) - Lung Score
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The King's Sarcoidosis Questionnaire (KSQ) - General Health. Results are given as a number between 1 to 100 with higher numbers indicating better health. The minimal clinically important difference (MCID) for KSQ remains unclear in sarcoidosis.
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The Leicester Cough Questionnaire items are scored on a 7-point Likert scale. A total score (range 3 to 21) is also calculated by adding the domain scores together, with higher scores indicating better quality of life. The MCID for chronic cough is 1.3.
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
The Steroid Toxicity Questionnaire (STQ) is a simple 12 question tool used to characterize the toxicity associated with steroid use using a 4-point scale. The MCID remains unclear in sarcoidosis. Higher scores indicate greater steroid toxicity
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Observed dose limiting toxicities (DLT), rate of adverse events of special interest (AESI) throughout the study duration between dose levels and frequencies
Tidsram: Baseline to Week 12

To determine the recommended Phase 2 dose level and frequency for XTMAB-16 in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Proportion of participants who achieve the targeted tapered dose of corticosteroid
Tidsram: Baseline to Week 12

To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use

Baseline to Week 12
Proportion of participants who achieve at least 50% reduction in dose of corticosteroid by Week 12
Tidsram: Baseline to Week 12

To observe the potential therapeutic effect of XTMAB-16 as measured by the ability to reduce background oral corticosteroid use

Baseline to Week 12
Total (systemic) clearance after intravenous (IV) dose in the intended participant population
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Volume of distribution after intravenous (IV) dose and an estimate of the volume of distribution at steady state based on single dose IV data parameters in the intended participant population
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Terminal elimination phase half-life expressed in time units in the intended participant population
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Accumulation ratio repeat dosing
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Area under the effect-time curve from time 0 (predose) to the last quantifiable effect -concentration time point, t (AUEC0-t)
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Maximum observed effect (Emax, obs)
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Time to reach Emax, obs (tEmax, obs)
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Absolute and percent change in biomarkers from Baseline to End of Infusion (EOI), Interleukin-6 (IL-6) and Soluble Tumor Necrosis Factor α (sTNFα)
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Number and percentage of participants by cohort who test positive for XTMAB-16 anti-drug antibodies (ADA) and transient & persistent positive status at follow-up assessments
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12
Number and percentage of participants by cohort who test positive for XTMAB-16 neutralizing antibody (nAb) and transient & persistent positive status at follow-up assessments
Tidsram: Baseline to Week 12

To evaluate the pharmacokinetics (PK) profile of XTMAB-16 and the effects on immunogenicity and biomarkers in participants with pulmonary sarcoidosis with or without extrapulmonary manifestations

Baseline to Week 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

10 november 2023

Primärt slutförande (Beräknad)

31 oktober 2026

Avslutad studie (Beräknad)

31 oktober 2026

Studieregistreringsdatum

Först inskickad

12 maj 2023

Först inskickad som uppfyllde QC-kriterierna

25 maj 2023

Första postat (Faktisk)

6 juni 2023

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera